Health
Moderna’s Future Clouded With Vaccines Facing New Pressures
- Shares fall by most on record after company cuts sales outlook
- Competition slows launch of its second product, an RSV vaccine
This article is for subscribers only.
Moderna Inc.’s post-pandemic future was thrown into question Thursday after it disclosed multiple setbacks that disappointed investors.
The biotech company has been largely shut out of the Covid vaccine market in Europe and expects low sales there. It’s facing increased competitive pressure in the US, leading to a disappointing launch of its new RSV vaccine.